November 1, 2018 / 8:10 AM / 14 days ago

BRIEF-Follicum Reports Top-Line Data From First Phase IIa Study With Fol-005

Nov 1(Reuters) - Follicum AB:

* REPORTED ON WEDNESDAY TOP-LINE DATA FROM THE FIRST PHASE IIA STUDY WITH FOL-005 FOR TREATMENT OF HAIR LOSS ON SCALP IN PATIENTS

* RESULTS CONFIRMED THAT THE TREATMENT WAS SAFE WITH MINIMAL SIDE EFFECTS REPORTED

* INCREASED HAIR GROWTH WAS MEASURED AT THE HIGHEST DOSE

* WILL NOW FOLLOW UP WITH A CLINICAL EFFICACY STUDY USING A TOPICAL FORMULATION OF FOL-005

* CEO: “WE ARE VERY PLEASED TO HAVE COMPLETED THIS PHASE IIA CLINICAL STUDY THAT HAS SHOWN THAT THE TREATMENT IS SAFE AND DESPITE THE LIMITED NUMBER OF PATIENTS”

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below